Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan

International Journal of Cardiology

Volumn 104, Issue 2, 2005, Pages 213-223

  Nagata Kobayashi, Shizuko ^a   Shimbo, Takuro ^a   Matsui, Kunihiko ^b   Fukui, Tsuguya ^a,c  

^a KYOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^c ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

Author keywords

HMG CoA reductase inhibitors; Hyperlipidemia; Myocardial infarction; Total serum cholesterol

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; MALE; MIDDLE AGED; PRAVASTATIN; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 24944487204     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.12.016     Document Type: Article

References (49)

1. A. Kitamura, H. Iso, and M. Iida Trends in the incidence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994 Am. J. Med. 112 2002 104 109
2. Statistics Bureau Ministry of public management, home affairs, posts, and telecommunications. Japan statistical yearbook, 2003 2002 The Institute Tokyo
3. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, and P.W. Macfarlane Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N. Engl. J. Med. 333 1995 1301 1307
4. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air force/Texas coronary atherosclerosis prevention study JAMA 279 1998 1615 1622
5. A. Hashimoto, T. Goto, and M. Uchibori Risk and benefit of cholesterol lowering drugs to prevent coronary heart disease in Japan J. Jpn. Atheroscler. Soc. 26 1998 157 164 [in Japanese]
6. L. Goldman, M.C. Weinstein, P.A. Goldman, and L.W. William Cost-effectiveness of HMG-CoA reductase inhibition of primary and secondary prevention of coronary heart disease JAMA 265 1991 1145 1151
7. D.M. Pickin, C.J. McCabe, and L.E. Ramsay Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment Heart 82 1999 325 332
8. L.A. Prosser, A.A. Stinnett, and P.A. Goldman Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics Ann. Intern. Med. 132 2000 769 787
9. S. Fujino, Y. Suzuki, K. Satoh, H. Imai, and T. Akazawa Cost effectiveness analysis about drug therapy of hyperlipidemia for coronary heart disease J. Clin. Ther. Med. 5 1989 461 490 [in Japanese]
10. T. Katayama, and A. Hisashige Economic evaluation of cholesterol-lowering therapy for hypercholesterolemia, cost-effectiveness of HMG-CoA reductase inhibitors Jpn. Pharmacol. Ther. 27 1999 747 758 [in Japanese]
11. R.B. D'Agostino Sr., S. Grundy, L.M. Sullivan, P. Wilson CHD Risk Prediction Group Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation JAMA 286 2001 180 187
12. Japan Atherosclerosis Society Japan Atherosclerosis Society (JAS) guideline for diagnosis and treatment of hyperlipidemias in adults. Investigating committee of guideline for diagnosis and treatment of atherosclerotic cardiovascular disease 2002 Japan Atherosclerosis Society Tokyo [in Japanese]
13. F.A. Sonnenberg, and J.R. Beck Markov models in medical decision making: a practical guide Med. Decis. Making 13 1993 322 338
14. M.R. Gold, J.E. Siegel, L.B. Russel, and M.C. Weinstein Cost-effectiveness in health and medicine 1996 Oxford Univ. Press New York (NY)
15. M.C. Weinstein for the Panel on Cost-Effectiveness in Health and Medicine Recommendations of the panel on cost-effectiveness in health and medicine JAMA 276 1996 1253 1258
16. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure Arch. Intern. Med. 157 1997 2413 2446
17. D.B. Petitti Meta-analysis, decision analysis, and cost-effectiveness analysis 2000 Oxford Univ. Press New York (NY)
18. K. Kodama, H. Sasaki, and Y. Shimizu Trend of coronary heart disease and its relationship to risk factors in a Japanese population: a 26 years follow up. Hiroshima/Nagasaki study Jpn. Circ. J. 54 1990 414 421
19. M. Saito, K. Fukami, and K. Hiramori Long-term prognosis of patients with acute myocardial infarction: is mortality and morbidity as low as the incidence of ischemic heart disease in Japan ? Am. Heart J. 113 1987 891 897
20. S. Hosoda, S. Kimata, and K. Tamura Follow-up of 2,733 Japanese patients with myocardial infarction Jpn. Circ. J. 59 1995 121 129
21. Guideline for diagnosis and treatment of hyperlipidemias in adults. Investigating committee of guideline for diagnosis and treatment of hyperlipidemia, Japan Atherosclerosis Society Doumyakukouka 25 1997 1 34 [in Japanese]
22. S. Tarui Japanese nationwide survey on primary hyperlipidemia 1986 Japanese Minisitry of Health and Welfare Tokyo [in Japanese]
23. A. Fukuda, T. Hayashi, T. Komazawa, S. Kusano, and T. Hashimoto The risk-stratified incidence of stroke and heart attack in Japan Health Control Rep. 9 1985 127 140 [in Japanese]
24. M. Konishi, N. Iida, and Y. Naitou Studies on the relationship between the trend of serum total cholesterol level and the incidence of cerebro-cardio-vascular diseases based on the follow-up studies in Akita and Osaka-with a special reference to the optimal serum total cholesterol level preventing both cerebral hemorrhage and coronary heart disease Atherosclerosis 15 1987 1115 1123 [in Japanese]
25. A. Kitamura, H. Iso, and Y. Naito High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men Circulation 89 1994 2533 2539
26. The Japanese Association for Cerebro-cardiovascular Disease Control. Research project on health risk appraisal for the prevention of ADL reduction and death from stroke. NIPPON DATA80 Research Report 1995: 35-81. in Japanese.
27. H. Itakura Results of clinical epidemiology and intervention trial of hyperlipidemia in Japan Nippon Rinsho 60 2002 889 898 [in Japanese]
28. Y. Saito, Y. Goto, and N. Nakaya Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test Atherosclerosis 72 1988 205 211
29. M. Matsuzaki, T. Kita, H. Mabuchi J-LIT Study Group Japan Lipid Intervention Trial Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia Circ. J. 66 2002 1087 1095
30. Division of Medicine, Department of Insurance, Japanese Ministry of Health and Welfare Interpretation of the social insurance reimbursement table 2000 Research Institute of Social Insurance Tokyo [in Japanese]
31. S.A. Finkler The distinction between cost and charges Ann. Intern. Med. 96 1982 102 109
32. Quality-of-life Policy Bureau. The report from working party for medical costs. Announcement in 07 March, 2001 [in Japanese].
33. M.F. Drummond, W.S. Richardson, B.J. O'Brien, M. Levine, and D. Heyland Users' guides to the medical literature: XIII. How to use an article on economic analysis of clinical practice. Are the results of the study valid? Evidence-Based Medicine Working Group JAMA 277 1997 1552 1557
34. K. Kawabuchi Precondition and environment for introduction of DRG/PPS of Japan 1996 Jihou Tokyo 184 185
35. The Tokyo hospital association, The report of the project for clinical outcome. Available from: URL: http://www.tmha.net/outcome/main.html.
36. D.G. Fryback, E.J. Dasbach, and R. Klein The Beaver Dam health outcomes study: initial catalog of health-state quality factors Med. Decis. Making 13 1993 89 102
37. J. Tsevat, L. Goldman, and J.R. Soukup Stability of time-tradeoff utilities in survivors of myocardial infarction Med. Decis. Making 13 1993 161 165
38. J.D. Stein, G.C. Brown, M.M. Brown, S. Sharma, H. Hollands, and H.D. Stein The quality of life of patients with hypertension J. Clin. Hypertens. 4 3 2002 181 188 [Greenwich]
39. A. Tsuchiya, T. Hasegawa, S. Nishimura, A. Hisashige, N. Ikegami, and S. Ikeda A validity study of the Japanese EuroQol instrument J. Health Care Soc. 8 1 1998 67 77 [in Japanese]
40. A.H. Briggs, R. Goeree, G. Blackhouse, and B.J. O'Brien Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease Med. Decis. Making 22 4 2002 290 308
41. J.W. Shaw, and W.M. Zachry Application of probabilistic sensitivity analysis in decision analytic modeling Prac. Pharmacoecon. 37 2002 32 40
42. I. Tsuji, A. Fukao, N. Sugawara, T. Shoji, I. Kuwajima, and S. Hisamichi Cost-effectiveness analysis of screening for gastric cancer in Japan Tohoku J. Exp. Med. 164 1991 279 284
43. T. Shimbo, H.A. Glick, and J.M. Eisenberg Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan Int. J. Technol. Assess. Health 10 1994 359 375
44. I. Okubo, H. Glick, H. Frumkin, and J.M. Eisenberg Cost-effectiveness analysis of mass screening for breast cancer in Japan Cancer 67 1991 2021 2029
45. S. Sato, G. Matunaga, I. Tsuji, A. Yajima, and H. Sasaki Determining the cost-effectiveness of mass screening for cervical cancer using common analytic models Acta Cytol. 43 1999 1006 1014
46. S. Nagata-Kobayashi, T. Shimbo, and T. Fukui Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women J. Bone Miner. Metab. 20 2002 350 357
47. I. Saito, A.R. Folsom, H. Aono, H. Ozawa, T. Ikebe, and T. Yamashita Comparison of fatal coronary heart disease occurrence based on population surveys in Japan and the USA Int. J. Epidemiol. 29 2000 837 844
48. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
49. R.P. Byington, B.R. Davis, J.F. Plehn, H.D. White, J. Baker, and S.M. Cobbe Reduction of stroke events with pravastatin: the prospective pravastatin pooling (PPP) project Circulation 103 2001 387 392